|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1523 News |
|
| «12...1213141516171819202122...3031» |
- | Inavir (laninamivir) / Daiichi Sankyo
Enrollment open: FROSTY: Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza (clinicaltrials.gov) - Dec 21, 2013
P1/2, N=48, Recruiting, Sponsor: Biota Scientific Management Pty Ltd
Active, not recruiting --> Recruiting
- Agriflu (trivalent influenza virus vaccine) / CSL Behring, FLUAD (trivalent inactivated influenza vaccine) / CSL Behring
Biomarker, Trial completion: Training Study to Characterize Biomarkers to Flu Vaccines (clinicaltrials.gov) - Dec 19, 2013
P1, N=49, Completed, Sponsor: University of Surrey
Active, not recruiting --> Recruiting Recruiting --> Completed
- | Vimizim (elosulfase alfa) / BioMarin
Enrollment change: Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation (clinicaltrials.gov) - Dec 19, 2013
P2, N=15, Active, not recruiting, Sponsor: BioMarin Pharmaceutical
Recruiting --> Completed N=20 --> 15
- | Vimizim (elosulfase alfa) / BioMarin
Enrollment closed: Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation (clinicaltrials.gov) - Dec 19, 2013
P2, N=15, Active, not recruiting, Sponsor: BioMarin Pharmaceutical
N=20 --> 15 Recruiting --> Active, not recruiting
- Enrollment closed: H7N9 Mix and Match With AS03 and MF59 in Healthy Adults (clinicaltrials.gov) - Dec 18, 2013
P2, N=980, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- ||| CR-8020 / AIM Therap
Trial completion: Assessment of CR8020, a Monoclonal Antibody Against Influenza A Viruses (clinicaltrials.gov) - Dec 17, 2013
P1, N=64, Completed, Sponsor: Crucell Holland BV
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- ||| Trial completion: Assessment of CR6261, a Monoclonal Antibody Against the Influenza A Virus (clinicaltrials.gov) - Dec 17, 2013
P1, N=64, Completed, Sponsor: Crucell Holland BV
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial initiation date: Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Nonpregnant HIV Uninfected Women (clinicaltrials.gov) - Dec 16, 2013
P4, N=150, Active, not recruiting, Sponsor: University of Witwatersrand, South Africa
Active, not recruiting --> Completed Initiation date: Mar 2013 --> Sep 2013
- | Inavir (laninamivir) / Daiichi Sankyo
New P1/2 trial: FROSTY: Safety & Pharmacokinetics Study of Inhaled Laninamivir Octanoate TwinCaps® Dry Powder Inhaler in Children With Influenza (clinicaltrials.gov) - Dec 16, 2013
P1/2, N=48, Recruiting, Sponsor: Biota Scientific Management Pty Ltd
- Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Enrollment closed: Immunogenicity and Safety of Trivalent Influenza Vaccine in Pregnant and Nonpregnant HIV Uninfected Women (clinicaltrials.gov) - Dec 16, 2013
P4, N=150, Active, not recruiting, Sponsor: University of Witwatersrand, South Africa
Initiation date: Mar 2013 --> Sep 2013 Not yet recruiting --> Active, not recruiting
- | New P1 trial, IO biomarker: Safety and Reactogenicity of a H1N1 Influenza Challenge Virus in Healthy Volunteers (clinicaltrials.gov) - Dec 16, 2013
P1, N=29, Completed, Sponsor: Immune Targeting Systems Ltd
- New P1 trial, IO biomarker: Safety and Immunogenicity of Co-administration of Candidate Influenza Vaccine MVA-NP+M1 and Viroflu® Seasonal Influenza Vaccine (clinicaltrials.gov) - Dec 16, 2013
P1, N=3, Terminated, Sponsor: University of Oxford
- Enrollment change: Dose Sparing Intradermal S-OIV H1N1 Influenza Vaccination Device (clinicaltrials.gov) - Dec 12, 2013
P=N/A, N=262, Completed, Sponsor: The University of Hong Kong
Not yet recruiting --> Active, not recruiting N=200 --> 262
- | Enrollment closed: Blood and Plasma Collection For Use in Future Clinical Trials (clinicaltrials.gov) - Dec 12, 2013
P=N/A, N=200, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=200 --> 262 Recruiting --> Active, not recruiting
- FluLaval Quadrivalent (influenza vaccine) / GSK
Enrollment closed: FluLaval® Quadrivalent Pregnancy Registry (clinicaltrials.gov) - Dec 11, 2013
P=N/A, N=1, Active, not recruiting, Sponsor: GlaxoSmithKline
Recruiting --> Active, not recruiting Not yet recruiting --> Active, not recruiting
- | Trial completion: Safety, Reactogenicity and Immunogenicity of GlaxoSmithKline (GSK) Biologicals' Non-typeable Haemophilus Influenzae (NTHI) Vaccine (clinicaltrials.gov) - Dec 11, 2013
P1, N=48, Completed, Sponsor: GlaxoSmithKline
Not yet recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Enrollment change: From Innovation to Solutions: Childhood Influenza Vaccination Planning (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=150, Completed, Sponsor: University of Pittsburgh
Active, not recruiting --> Completed N=20300 --> 150
- |||||||||| favipiravir / Generic mfg.
New P3 trial, P3 data: Phase 3 Efficacy and Safety Study of Favipiravir for Treatment of Uncomplicated Influenza in Adults (clinicaltrials.gov) - Dec 9, 2013
P3, N=1056, Recruiting, Sponsor: MDVI, LLC
- | Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Enrollment closed: Immunogenicity and Safety of Different Dosing Schedules of Trivalent Influenza Vaccine in HIV-infected Pregnant Women (clinicaltrials.gov) - Dec 9, 2013
P3, N=789, Active, not recruiting, Sponsor: University of Witwatersrand, South Africa
N=20300 --> 150 Recruiting --> Active, not recruiting
- Trial completion: From Innovation to Solutions: Childhood Influenza Vaccination Planning (clinicaltrials.gov) - Dec 9, 2013
P=N/A, N=150, Completed, Sponsor: University of Pittsburgh
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial initiation date: Effect of HIV and/or Active Tuberculosis on the Immune Responses to Trivalent Influenza Vaccine (TIV) in Adults (clinicaltrials.gov) - Dec 9, 2013
P4, N=360, Not yet recruiting, Sponsor: University of Witwatersrand, South Africa
Active, not recruiting --> Completed Initiation date: Mar 2013 --> Mar 2014
- Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Enrollment change: Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women (clinicaltrials.gov) - Dec 9, 2013
P4, N=105, Completed, Sponsor: University of Witwatersrand, South Africa
Initiation date: Mar 2013 --> Mar 2014 N=200 --> 105
- New P1 trial: Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study (INSIGHT 005: Flu-IVIG Pilot) (clinicaltrials.gov) - Dec 9, 2013
P1, N=40, Recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
Trial completion: Immunogenicity and Safety of Trivalent Influenza Vaccine in Non-pregnant HIV-infected Women (clinicaltrials.gov) - Dec 9, 2013
P4, N=105, Completed, Sponsor: University of Witwatersrand, South Africa
N=200 --> 105 Not yet recruiting --> Completed
- ||| Trial completion: Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years (clinicaltrials.gov) - Dec 8, 2013
P1, N=200, Completed, Sponsor: VaxInnate Corporation
Not yet recruiting --> Completed Active, not recruiting --> Completed
- ||| Fluzone (influenza vaccine) / Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Enrollment change: A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults (clinicaltrials.gov) - Dec 4, 2013
P4, N=31989, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
Active, not recruiting --> Completed N=17501 --> 31989
- |||| Fluzone (influenza vaccine) / Sanofi, Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion: A Study of Fluzone® High-Dose Vaccine Compared With Fluzone® Vaccine In Elderly Adults (clinicaltrials.gov) - Dec 4, 2013
P4, N=31989, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
N=17501 --> 31989 Active, not recruiting --> Completed
- Fluzone (influenza vaccine) / Sanofi, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion: Post-Partum Immunization With Live Attenuated Influenza Vaccine (LAIV) or Trivalent Influenza Vaccine (TIV) in Post-Partum Breast Feeding Women (clinicaltrials.gov) - Dec 4, 2013
P2, N=240, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Fluvirin (inactivated influenza virus vaccine) / CSL Behring, Fluzone (influenza vaccine) / Sanofi
Trial termination: Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy (clinicaltrials.gov) - Dec 3, 2013
P=N/A, N=21, Terminated, Sponsor: Washington University School of Medicine
Active, not recruiting --> Completed Recruiting --> Terminated; no longer had funding to continue
- Fluvirin (inactivated influenza virus vaccine) / CSL Behring, Fluzone (influenza vaccine) / Sanofi
Enrollment change: Response to Influenza Vaccine in Patients With Non-Hematologic Malignancies Receiving Chemotherapy (clinicaltrials.gov) - Dec 3, 2013
P=N/A, N=21, Terminated, Sponsor: Washington University School of Medicine
Recruiting --> Terminated; no longer had funding to continue N=300 --> 21
- ||| GSK3206641A / GSK, GSK3206640A / GSK
New P1 trial: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age (clinicaltrials.gov) - Dec 1, 2013
P1, N=424, Active, not recruiting, Sponsor: GlaxoSmithKline
- |||||||||| New P3 trial, Preclinical: A Study to Evaluate the Safety of Two Influenza Vaccines in Children and Adolescents 3 to <18 Years of Age at Risk for Influenza-Related Complications (clinicaltrials.gov) - Nov 27, 2013
P3, N=430, Active, not recruiting, Sponsor: Novartis Vaccines
- ||||||| Flublok (influenza vaccine) / Sanofi, Ildong, Shionogi
Trial completion: A Study to Evaluate Intramuscular ASP7374 (clinicaltrials.gov) - Nov 25, 2013
P3, N=55, Completed, Sponsor: Astellas Pharma Inc
N=300 --> 21 Not yet recruiting --> Completed
- ||||||| Flublok (influenza vaccine) / Sanofi, Ildong, Shionogi
Trial completion, Preclinical: Study of ASP7374, Cell-culture-derived Influenza Vaccine (clinicaltrials.gov) - Nov 25, 2013
P3, N=900, Completed, Sponsor: Astellas Pharma Inc
Not yet recruiting --> Completed Recruiting --> Completed
- H7N9 Anhui 2013/AA ca / National Institute of Allergy and Infectious Diseases
New P1 trial: Safety and Immunogenicity of a Live Attenuated H7N9 Influenza Virus Vaccine in Healthy Adults (clinicaltrials.gov) - Nov 24, 2013
P1, N=48, Active, not recruiting, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
- |||||||||| New P3 trial, Head-to-Head: Safety and Immunogenicity of Three Influenza Vaccines Adults Ages 18 and Older (clinicaltrials.gov) - Nov 21, 2013
P3, N=2680, Active, not recruiting, Sponsor: Novartis Vaccines
- |||||||||| New P3 trial, Head-to-Head: Safety and Immunogenicity of Three Influenza Vaccines in Children Aged 4 Years Old to Less Than 18 Years Old (clinicaltrials.gov) - Nov 21, 2013
P3, N=2349, Active, not recruiting, Sponsor: Novartis Vaccines
- CR-8020 / AIM Therap
New P2 trial: Assessment of Efficacy of CR8020 and CR6261, Monoclonal Antibodies, Against Influenza Infection (clinicaltrials.gov) - Nov 21, 2013
P2, N=0, Withdrawn, Sponsor: Crucell Holland BV
- | New P1 trial: Safety, Tolerability, and PK of Escalating Doses of Flufirvitide-3 Dry Powder for Inhalation in Healthy Subjects (clinicaltrials.gov) - Nov 21, 2013
P1, N=48, Recruiting, Sponsor: Autoimmune Technologies, LLC
- | Fluarix Quadrivalent (influenza vaccine) / GSK
Trial completion: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345 (clinicaltrials.gov) - Nov 20, 2013
P3, N=468, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| Dectova (zanamivir) / GSK
Enrollment change: ZORO: A Study of Intravenous Zanamivir Versus Oral Oseltamivir in Adults and Adolescents Hospitalized With Influenza (clinicaltrials.gov) - Nov 20, 2013
P3, N=600, Recruiting, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed N=462 --> 600
- |||||| Plegridy (PEG-interferon ?-1a) / Biogen
Enrollment open: Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-?) Therapies to Peginterferon Beta-1a (BIIB017) (clinicaltrials.gov) - Nov 20, 2013
P3, N=200, Recruiting, Sponsor: Biogen Idec
N=462 --> 600 Not yet recruiting --> Recruiting
- Enrollment change: Long Term Follow up of Patients Who Were Treated With Extracorporeal Membrane Oxygenation for Pandemic Influenza A/H1N1 Induced Severe Respiratory Failure (clinicaltrials.gov) - Nov 19, 2013
P=N/A, N=7, Completed, Sponsor: Karolinska University Hospital
Not yet recruiting --> Recruiting N=12 --> 7
- Enrollment change: Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon (clinicaltrials.gov) - Nov 19, 2013
P=N/A, N=129, Completed, Sponsor: St. Jude Children's Research Hospital
N=12 --> 7 N=300 --> 129
- Trial completion: Long Term Follow up of Patients Who Were Treated With Extracorporeal Membrane Oxygenation for Pandemic Influenza A/H1N1 Induced Severe Respiratory Failure (clinicaltrials.gov) - Nov 19, 2013
P=N/A, N=7, Completed, Sponsor: Karolinska University Hospital
N=300 --> 129 Recruiting --> Completed
- Trial completion: Case-control Study of Pandemic A/H1N1 Influenza Risk Factors In Lebanon (clinicaltrials.gov) - Nov 19, 2013
P=N/A, N=129, Completed, Sponsor: St. Jude Children's Research Hospital
Recruiting --> Completed Active, not recruiting --> Completed
- | FluMist (influenza vaccine, live, intranasal) / AstraZeneca, Fluzone (influenza vaccine) / Sanofi, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
New P4 trial: T-cell And General Immune Response to Seasonal Influenza Vaccine (SLVP018) - Year 1, 2009 (clinicaltrials.gov) - Nov 17, 2013
P4, N=550, Active, not recruiting, Sponsor: Stanford University
- |||||||||| MG1109 / Green Cross
New P3 trial: Phase III Study to Evaluate the Immunogenicity and Safety of MG1109 in Healthy Adult Volunteers (clinicaltrials.gov) - Nov 17, 2013
P3, N=420, Completed, Sponsor: Green Cross Corporation
- |||||||||| Infanrix Hexa (diphtheria tetanus toxoids, acellular pertussis, hepatitis B (recombinant), inactivated poliomyelitis, adsorbed conjugated Haemophilus influenzae type b vaccine) / GSK
New P3 trial: Antibody Persistence at Age 3.5 and 4.5 Years After Primary and Booster DTaP-IPV-Hep B-PRP~T or Infanrix Hexa Vaccination (clinicaltrials.gov) - Nov 12, 2013
P3, N=688, Enrolling by invitation, Sponsor: Sanofi Pasteur, a Sanofi Company
- New P1 trial: Reactogenicity, Safety and Immunogenicity of a Live Monovalent A/17/CALIFORNIA/66/395 (H2N2) Influenza Vaccine (clinicaltrials.gov) - Nov 11, 2013
P1, N=40, Completed, Sponsor: PATH